Elanco Animal Health FY Conference Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date of Conference**: March 10, 2026 - **Key Speakers**: Bob VanHimbergen (CFO), Bobby Modi (Head of U.S. Pet Health and Global Digital Transformation) Key Points Financial Performance - **Q4 2025 Performance**: - Revenue growth of 9% organically - U.S. Pet Health business grew by 10% - U.S. farm business grew by 17% - International business also performed well with 9 countries showing growth and all top 5 franchises increasing sales [6][19] - **2026 Guidance**: - Mid-single-digit top-line growth - High single-digit EBITDA growth - Low double-digit EPS growth - Deleveraging target to below 3 times by 2027 [6][55] Innovation and Product Launches - **Innovation Basket**: - Contributed over $400 million in growth year-over-year - Expected to grow by an additional $250 million in 2026 [22][55] - **New Product Launches**: - Launched 12 differentiated assets in the last 3 years, contributing to market share growth [10] - Quattro and Zenrelia are highlighted as key products driving growth [28][46] Market Dynamics - **U.S. Pet Health**: - Strong growth driven by new product launches and increased market share in various categories including pain, vaccines, and parasiticides [10][28] - Combo products are growing rapidly, with 30% growth in the category and two-thirds of puppies starting on combo products [33][34] - **Farm Business**: - Grew 17% in Q4, led by cattle and poultry, with the Experior product crossing $200 million in revenue [19][20] - International farm business grew by 4%, driven by global protein demand [21] Pricing Strategy - **Pricing Dynamics**: - 2% price increase in 2025 with 5% volume growth - Expecting acceleration in pricing for 2026 [15][16] - **Market Positioning**: - Focus on value-based pricing and maintaining a balance between volume and pricing [15][16] Competitive Landscape - **Zenrelia's Market Position**: - Gained significant market share in Brazil (40%) and Japan (30%) [21][37] - Anticipated to perform well against new competitors due to its efficacy and established market presence [46] Future Outlook - **Long-term Growth**: - Industry expected to grow by $20 billion over the next decade, with opportunities in both pet and farm segments [62] - Continued investment in R&D to ensure a robust pipeline of new products [51][65] - **Margin Improvement**: - Expected net EBITDA improvement of $200-$250 million by 2030 through operational efficiencies and cost management [58][59] Additional Insights - **Consumer Trends**: - Increased willingness to spend on pet care, supporting growth in the animal health market [62][65] - **Omni-channel Strategy**: - Focus on providing products through various channels to meet consumer preferences [64][65] This summary encapsulates the key insights and financial performance of Elanco Animal Health as discussed in the FY conference, highlighting growth drivers, market dynamics, and future outlook.

Elanco Animal Health Conference Call Summary Company Overview - **Company**: Elanco Animal Health - **Industry**: Animal Health Key Takeaways from Q4 Results - **Growth**: Elanco reported a 9% growth in Q4 2025, with a total revenue of $892 million from its innovation basket for the year [2][3] - **Debt Management**: The company successfully paid down more debt than projected, achieving a leverage ratio of 3.6 times [2] - **2026 Guidance**: Elanco expects mid-single-digit top line growth, high-single-digit EBITDA growth, and low-double-digit EPS growth for 2026, with plans to reduce leverage into the low 3s [3] Product Performance and Innovation - **Basket of Innovation**: The innovation basket is expected to generate $1.15 billion in revenue for 2026, up from $892 million in 2025 [22] - **Key Products**: Products like Zenrelia and Quattro are highlighted as significant contributors to growth, with Zenrelia already in 40 countries and Quattro achieving blockbuster status in just 8 months [22][36] - **Seresto Brand**: Seresto's sales are approximately 50% from the U.S. market, with limited expected impact from generics due to strong brand loyalty and distribution channels [9][10] Market Trends and Consumer Behavior - **Pet Market Dynamics**: About 40% of sales in the pet market are subscription-based, with omnichannel shoppers spending 30% more than single-channel shoppers [13] - **Animal Protein Consumption**: U.S. animal protein consumption is projected to grow at about 5% annually, driven by changing dietary guidelines and an aging population [14] Competitive Landscape - **Competition Awareness**: Elanco acknowledges the competitive environment but believes its products, particularly Zenrelia and Quattro, are well-positioned to succeed [4][17] - **Market Share**: Elanco has seen significant growth in corporate accounts, with a 90% increase compared to 13% the previous year [18] Financial Outlook and Cost Management - **Pricing Strategy**: Elanco plans to continue pricing to value, with an expected acceleration in pricing in 2026 [15] - **Cost Savings Initiatives**: The Elanco Ascend program aims to improve EBITDA by $200 million-$250 million by 2030, focusing on cost management and operational efficiencies [28][44] Regulatory and Label Updates - **Zenrelia Label**: The company is in discussions with the FDA regarding potential label enhancements, which could provide a tailwind for the business [36][38] Long-term Strategy - **Future Growth**: Elanco aims to launch five to six potential blockbusters by 2031, focusing on innovation and strengthening its balance sheet [61] - **Acquisition Strategy**: Future acquisitions will focus on both pet and farm animal segments, primarily around R&D [45][49] Conclusion - Elanco is entering a new era of growth, leveraging its innovation pipeline and strong market position to capitalize on industry trends and consumer behavior, while managing competition and regulatory challenges effectively [60][61]

Financial Performance and Outlook - Elanco expects organic constant currency revenue growth starting in 2025[10] - The company anticipates adjusted EBITDA growth starting in 2026[10] - Elanco projects over $1 billion in total free cash flow from 2026 to 2028[10] - The company aims to reduce net leverage to below 3x in 2027 and further towards 20x-25x[10] - Elanco expects innovation to deliver $11 billion in revenue in 2026, compared to $840-$880 million in 2025[90] Innovation and Pipeline - Elanco's innovation engine is expected to generate $840-$880 million in revenue in 2025[34] - The "Big 6" products are projected to drive $11 billion in innovation revenue in 2026[39] - The company anticipates 5-6 potential blockbuster approvals between 2026 and 2031, with peak sales exceeding $2 billion[10, 61, 90] - Elanco's "Next Wave" innovation portfolio includes over 15 projects across 8 innovation spaces[58, 59] Market and Industry Trends - The animal health industry is projected to grow from $42 billion to $60 billion[11] - The pet health industry is a $17 billion market experiencing mid-single-digit to high-single-digit growth[16] - The farm animal health industry is a $25 billion market with low-single-digit to mid-single-digit growth[17] Elanco Ascend and Cost Savings - Elanco Ascend is expected to generate approximately $200-$250 million in adjusted EBITDA savings by 2030, net of inflation and reinvestment[71, 90] - The company anticipates approximately $25 million in savings in 2026, $60 million in 2027, and $130 million in cash cost[90]

Elanco Animal Health FY Conference Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date of Conference**: December 04, 2025 Key Industry Insights - **Industry**: Animal Health - **Market Size**: The U.S. pet health market is transforming into a growth business, with significant contributions from innovation and differentiated products [7][10] - **Dermatology Market**: The U.S. dermatology market is valued at $1.3 billion, growing at double digits, while the global market is approximately $2 billion [10] Core Points and Arguments Margin Expansion and Cost Management - Elanco is focusing on margin expansion through innovation, with a higher margin on new products compared to corporate averages [3] - The Elanco Ascend initiative aims to improve margins through cost management, automation, and strategic supplier partnerships [5][6] - Expected EBITDA growth in 2026 due to cost measures and investments in R&D and marketing [6] Product Innovations and Market Performance - **Zenrelia**: Achieved significant growth with total sales doubling from Q2 to Q3, and clinic penetration reaching 45% [10][11] - **Quattro**: Exceeding growth expectations, with a focus on broad-spectrum parasiticide market [12][30] - **Experior**: A key product in the farm animal segment, with a market potential of $350 million in the U.S. and Canada [12][23] Farm Animal Business Insights - The farm business represents half of Elanco's operations, with EBITDA margins comparable to the pet side [19][23] - The market for farm products is stable and growing, with a $25 billion market size [23] - Bovaer, another product, has shown strong customer retention rates despite muted growth due to lack of government incentives [24][26] Competitive Landscape and Market Strategy - Elanco is prepared for competitive product launches, having factored them into their business outlook [58] - The company emphasizes differentiation in its product offerings, particularly in the parasiticide market [58] Financial Performance and Deleveraging Strategy - Elanco has successfully reduced its debt from 5.6 times to an expected 3.738 times by the end of 2025, with a goal to be below three times by 2027 [43][44] - The company plans to maintain a balanced capital allocation strategy focused on debt reduction and business investment [61][62] Future Outlook and Investor Day - Upcoming Investor Day will provide detailed insights into growth strategies, manufacturing capabilities, and financial projections for the next three years [67] Additional Important Points - The humanization of pets is driving increased spending on pet health, with consumers willing to invest more in their pets' well-being [36] - Elanco's strategy includes a diverse portfolio to mitigate the impact of declining veterinary visits [37][38] - The company is leveraging its OTC portfolio to cater to consumers who do not visit vets regularly [37] This summary encapsulates the key insights and strategic directions discussed during the Elanco Animal Health FY Conference, highlighting the company's focus on innovation, market growth, and financial stability.

Elanco Animal Health FY Conference Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date of Conference**: December 03, 2025 Key Points Industry Insights - The animal health industry is experiencing significant growth, particularly in the animal protein sector, with a notable demand for chicken products [2][3] - The market for oral broad-spectrum parasiticides is valued at approximately $1.4 billion and is growing at 40% [10] - The derm market is the second largest, valued at $2 billion and growing at double digits [10] Financial Performance - Elanco has achieved nine consecutive quarters of growth, with an increasing quality and size of growth [3] - The company aims to reduce its debt from 3.7 times to low threes or high twos, prioritizing this as the number one use of cash [7][8] - EBITDA growth is expected to be driven by better margins from blockbuster products and a productivity initiative called Elanco Ascend [8][16] Innovation and Product Development - Elanco has a robust pipeline with six approved products and anticipates a seventh product, IL-31, to be added soon [3][11] - The company is focusing on a mix of farm and pet innovations, which is unique compared to competitors [28] - Quattro, a new product, is gaining market share rapidly, with 75% of its sales coming from competitors' products [22] Market Position and Competition - Elanco is positioned to capture market share from larger competitors like Zoetis, particularly in large veterinary practices [22] - The company is experiencing competitive pressure in the U.S. pet health market, but differentiation in product offerings is key to maintaining value [23] Future Outlook - Elanco is optimistic about its growth trajectory and plans to provide more detailed guidance for 2026 in the upcoming week [4][31] - The company is committed to maintaining a consistent flow of high-impact innovations and believes it is a compelling investment proposition in the animal health space [13] Additional Considerations - The company has launched a five-year productivity initiative, Elanco Ascend, aimed at improving procurement, manufacturing, and overall productivity [16] - There is a focus on both top-line revenue growth and EBITDA growth, with expectations for a meaningful dropdown to EBITDA levels from new product revenues [14][15] Conclusion - Elanco Animal Health is positioned for continued growth through innovation, strategic debt management, and a focus on market differentiation. The upcoming guidance for 2026 is anticipated to provide further clarity on the company's growth trajectory and financial health [31]

a first on CNBC interview is Elanco CEO Jeff Simmons. Jeff, I just want to talk about this because I have a personal interest as an owner of two dogs. And I want to say now, six fish.At this point, we have animals throughout our house. Our kids love them. What exactly is driving the demand for animal health products.To the point that we've seen your stock jump the way that it did. >> Tom, great to be with you this morning. And it's exactly that.And that is that the personalization of that pet in the home, t ...

Summary of Elanco Animal Health Conference Call Company Overview - **Company**: Elanco Animal Health - **Industry**: Animal Health Key Points and Arguments Financial Performance - Elanco reported a robust Q1 with a **4% constant currency revenue growth**, marking the **seventh consecutive quarter of growth** [4][5] - The company exceeded guidance on revenue, adjusted EBITDA, and adjusted EPS [5] - Revenue guidance was raised to **$660 million to $740 million** for the innovation basket initiated in 2021 [6] Innovation and Product Development - The innovation basket includes six key products contributing significantly to growth, particularly **Quattro**, **Experior**, and **ZENRELIA** [7][8] - **Experior** is identified as having a **$350 million potential market** in North America [8] - ZENRELIA is gaining traction with **11,000 clinics** adopting it, indicating strong market demand in the **$1.9 billion dermatology market** [25][26] - The derm market is expected to grow **double digits**, with ZENRELIA positioned as a leading product [25] Cash Flow and Debt Management - Elanco announced monetizing royalties on the Lotta Lanner asset, bringing in nearly **$300 million** for debt reduction [9] - The company anticipates **$450 million to $500 million** for debt paydown, improving leverage ratios [9] Tariff and Regulatory Environment - Elanco is actively managing tariff impacts, estimating a **$16 million to $20 million** effect primarily from U.S.-China trade relations [10][11] - The company is engaged in discussions with the administration regarding potential tariff exemptions for the animal health industry [16][19] - Regulatory reform discussions are ongoing, with a focus on streamlining processes with the FDA and USDA [17][34] Market Dynamics and Competitive Landscape - The farm animal segment is experiencing growth, with Elanco being a leader in beef, swine, and poultry [73] - The company is optimistic about the protein market, noting a **20% decline** in animal protein alternatives [74] - Elanco's competitive strategy includes leveraging its innovation pipeline and addressing market needs effectively [46][87] Future Outlook - Elanco is focused on expanding its product portfolio, with plans for **seven blockbuster products** in the pipeline [87] - The company is enhancing its distribution strategy, increasing physical availability across various retail channels [90][92] - The outlook for the farm animal segment remains positive, with specific growth anticipated in cattle and poultry, while the pig industry faces challenges [99] Additional Insights - Elanco emphasizes the importance of a stable core business supported by innovation, which is crucial for sustained growth [100] - The company is committed to maintaining a competitive edge through scientific rigor and addressing consumer demands for sustainability [80][81] Conclusion Elanco Animal Health is positioned for continued growth through innovation, effective management of market dynamics, and a strong focus on regulatory engagement. The company's diverse product portfolio and strategic initiatives in the animal health sector are expected to drive future performance.